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ABSTRACT
Objective: To assess the relationships among ABO group, factor VIII (FVIII), and incident cognitive
impairment in a large, prospective cohort study of black and white adults in the United States
using a nested case-control design.
Methods: Incident cognitive impairment was defined using cognitive domain tests over a mean
follow-up of 3.4 years. ABO blood group was measured by genotyping in a nested case-control
sample of 495 cases with cognitive impairment and 587 controls.
Results: Those with blood group AB and those with higher FVIII had an increased risk of cognitive
impairment, adjusting for age, race, region, and sex (respective odds ratios 1.82, 95% confi-
dence interval [CI] 1.15–2.90; and 1.24, 95% CI 1.10–1.38 for 40 IU/dL higher FVIII). Mean
FVIII was higher in those with blood type AB (142 IU/dL; 95% CI 119–165) compared with O
(104 IU/dL; 95% CI 101–107), and FVIII mediated 18% of the association between AB group
and incident cognitive impairment (95% CI for mediation 230% to 68%).
Conclusions: Blood group AB and higher FVIII were associated with increased incidence of cogni-
tive impairment in this prospective study. The association of blood group AB with incident cogni-
tive impairment was not significantly mediated by FVIII levels. Neurology® 2014;83:1271–1276
GLOSSARY
CHD 5 coronary heart disease; CI 5 confidence interval; CVD 5 cardiovascular disease; FVIII 5 factor VIII; REGARDS 5
Reasons for Geographic and Racial Differences in Stroke; SNP 5 single nucleotide polymorphism; vWF 5 von Willebrand
factor.
There is a growing understanding that cardiovascular disease (CVD) and cognitive impairment
share many common risk factors. Hypertension,1,2 elevated cholesterol,3 hyperglycemia,2,4 and
obesity4,5 are all associated with longitudinal declines in cognitive function and dementia.
Higher levels of the hemostatic markers von Willebrand factor (vWF), coagulation factor VIII
(FVIII), and D-dimer have also been related to risk of cognitive impairment and dementia.6–9
ABO blood group is associated with many forms of CVD, including coronary heart disease
(CHD), stroke, and venous thromboembolism.10–12 In general, individuals with blood group O
have a reduced risk of CVD.13,14 Non-O blood types are associated with higher levels of vWF
and FVIII, procoagulant proteins that circulate as a complex in blood,11,12 because the ABO
antigen affects clearance of vWF.15 Levels of both vWF and FVIII are associated with throm-
bosis,16 and were recently linked to dementia risk.17 A recent report demonstrating an associ-
ation between blood type AB and stroke risk found that 60% of that association was mediated
by differences in FVIII level.18
Although ABO blood group is a CVD risk factor, we are not aware of studies on its relation-
ship with cognitive impairment. In this study, we examined the relationships among ABO
group, FVIII, and incident cognitive impairment in the Reasons for Geographic and Racial Dif-
ferences in Stroke (REGARDS) cohort. We hypothesized that blood group A, B, or AB would
be associated with an increased risk of cognitive impairment relative to group O.
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METHODS Cohort. The REGARDS cohort consists of 30,239
individuals throughout the contiguous United States, aged 45 years
and older when recruited between 2003 and 2007. The primary
purpose of the REGARDS Study is to investigate the reasons for
regional and racial differences in stroke mortality. All participants
were self-identified as black or white, with 55% of participants
female, 41% black, and 56% living in the southeastern Stroke
Belt (North Carolina, South Carolina, Georgia, Alabama,
Mississippi, Tennessee, Arkansas, and Louisiana). Detailed
information on the recruitment and demographics of this group
has been previously published.19 Demographic and medical
history information was collected by telephone interview and in
subsequent in-home visits; anthropomorphic data, blood samples,
and medication inventory were collected.
Standard protocol approvals, registrations, and patient
consents. All subjects gave informed consent to study participa-
tion. All study procedures were approved by the institutional
review boards of the collaborating institutions.
Cognitive assessments. Incident cognitive impairment was
defined based on 4 cognitive tests administered during phone inter-
views: a baseline 6-item screener and a follow up 3-test measure
including an animal fluency test, a word list learning test, and
word list recall. The 6-item screener consists of 3 immediate recall
and 3 temporal orientation items, and was introduced 11 months
after the study began and performed annually thereafter. Animal
fluency is a verbal fluency test scored as the number of animals
that a participant can name in 60 seconds, and word list learning
and word list recall measure ability to learn and recall a 10-item list.
Our goal was to identify clinically significant cognitive impair-
ment at the individual subject level. To do this, we started by select-
ing a performance cutoff that reflects a truly rare and poor test
performance, i.e., $1.5 SD below the mean of the population.
This is a frequently used performance threshold in the diagnostic
criteria for mild cognitive impairment.20,21 Scores on these tests
were considered impaired if they were below 1.57 SDs from the
age-, race-, sex-, and education-adjusted mean scores; this cutpoint
was selected to provide approximately 500 cases with substantial
impairment in this cohort. Participants were considered to have
incident cognitive impairment if, over the course of the study, they
had no cognitive impairment at the baseline 6-item screener and an
impaired score on at least 2 of the other 3 tests during follow-up.22
Requiring impaired scores in at least 2 of the tests was intended to
further select for significant cognitive impairment. The mean
follow-up time was 3.4 years.
Case-control study design. A case-control study design was
used to allow efficient study of genetic and biomarker
relationships with cognitive decline and provide results that
would approximate those that might be obtained by measuring
biomarkers in the entire cohort. Among the 30,239 REGARDS
participants, we excluded those with prebaseline stroke, baseline
cognitive impairment on the 6-item screener, insufficient
cognitive testing, or anomalous data. This yielded 17,630
participants eligible for the study, with 495 cases of incident
cognitive impairment. Unmatched controls consisted of the
587 participants without cognitive impairment who met these
eligibility criteria and were also part of a 1,100-person cohort
random sample of REGARDS participants selected for a case-
cohort study of stroke risk factors. The cohort random sample
was created using stratified sampling to ensure representation of
black and white subjects, men and women, and age groups 45
to 54 years (20%), 55 to 64 years (20%), 65 to 74 years
(25%), 75 to 84 years (25%), and 85 years or older (10%), in
an otherwise randomly selected sample.23
Laboratory. Fasting blood samples for REGARDS were drawn
during in-home visits. Processing, which included centrifugation
for 10 minutes and transfer of serum, plasma, or cells into mailer
tubes, was required within 120 minutes of the sample collection
(mean [SD]: 97 [127] minutes). The samples were then shipped
on ice overnight to the study laboratory at the University of
Vermont, where they were recentrifuged (30,000g) at 4°C for
15 minutes, aliquoted into cryovials, and stored at 280°C. To
determine the validity of FVIII antigen measurements and other
biomarkers assessed by REGARDS, given this sample collection
and processing protocol, a comparison was done between
simulated REGARDS sample processing and ideal processing
(performed immediately after sample collection) using 20 split
samples. In these experiments, and among cognitive impairment
cases and controls, FVIII antigen was measured using an ELISA
with a coefficient of variability range of 4% to 7% (Enzyme
Research Laboratories, South Bend, IN). The Spearman rank
correlation for FVIII processed using ideal methods compared
with REGARDS methods was 0.92. Six single nucleotide
polymorphisms (SNPs), rs507666, rs687289, rs8176704,
rs8176720, rs7853989, and rs8176749, determined using
TaqMan probes (Life Technologies, Grand Island, NY), were
used to construct ABO haplotypes.
Covariates. Race, either black or white, was established by par-
ticipant self-report. Diabetes was defined as fasting glucose$126
mg/dL, nonfasting glucose $200 mg/dL, self-reported physician
diagnosis of diabetes, or self-reported use of diabetes medication.
Dyslipidemia was defined as total cholesterol $240 mg/dL,
low-density lipoprotein $160 mg/dL, high-density lipoprotein
#40 mg/dL, or use of cholesterol-lowering medications.
Hypertension was defined as systolic blood pressure $140 mm
Hg or diastolic blood pressure $90 mm Hg or self-reported use
of antihypertensive medications. Baseline CHD included ECG
evidence of myocardial infarction or self-reports of myocardial
infarction, coronary artery bypass, stent, or angioplasty.
Baseline CVD was defined as baseline CHD or peripheral
artery disease.
Statistical analysis. Diplotype probabilities determined by the 6
ABO SNP identities were calculated using PHASE 2.1 (University
of Washington, Seattle). These diplotypes were then classified into
blood group A, B, AB, or O, based on the genotype of 4 informa-
tive SNPs (rs507666, rs687289, rs8176704, and rs8176749).24
This genotyping predicted ABO type with .90% certainty in
1,015 of 1,082 participants (94%), and these individuals were
assigned to a single blood group. Those with uncertain or incom-
plete haplotype information were assigned diplotype probabilities
by the software, based on their available SNP data and population
frequencies stratified by race. All analyses were weighted for these
blood type probabilities.
Statistical analyses were performed using SAS 9.3 (SAS Insti-
tute, Cary, NC). All analyses were weighted to account for blood
type probabilities and control sample stratification. This was done
by creating 4 individual records for every participant, each corre-
sponding to a blood group (O, A, B, and AB), and weighted with
the probability for that blood type. For example, if an individual
had a 60% probability of blood type A, a 30% probability of type
O, and a 10% probability of type B, they would be represented as
4 individuals with weights of 0.6, 0.3, 0.1, and 0. Categorical cor-
relates of blood type were determined using weighted logistic
regression or the Rao-Scott x2 with a 95% confidence interval
(CI) calculated by Taylor series using finite population correc-
tion. For continuous variables, differences in means among blood
groups were analyzed using weighted linear regression.
1272 Neurology 83 September 30, 2014
The relationships of blood group, FVIII, and incident cogni-
tive impairment were evaluated with weighted logistic regression
models. Blood group O was used as the reference group because it
is associated with lower CVD risk than non-O groups. Interac-
tion between race and blood group was tested by including a race
3 blood group term in the models. Model 1 was adjusted for age,
race, region of residence, and sex. The role of FVIII as a potential
mediator of the association between blood group and cognitive
impairment was assessed by adding it to age, sex, and race in
model 2. Model 3 was adjusted for all previous variables and also
baseline CVD. Model 4 was additionally adjusted for CVD risk
factors. The mediating effect of FVIII on the blood group asso-
ciation in model 2 was investigated by bootstrapping with 1,000
replicate samples, and a CI for the change in the OR for blood
type and incident cognitive impairment was estimated.
RESULTS Table 1 presents the distribution of cardi-
ovascular risk factors in the incident cognitive impair-
ment cases (495) and controls (587 weighted to
17,122). Missing data represented no more than
5% for any variables. Cases were more likely than
controls to live in the Stroke Belt region, be smokers,
and have hypertension, hyperlipidemia, diabetes, and
CVD. There were no significant differences in age,
race, and sex, because these factors were accounted for
in the definition of cognitive impairment.
The distribution of blood types in cases and con-
trols is presented in table 2. Cases were more likely to
be blood type AB compared with controls. In both
cases and controls, black individuals were more likely
than white individuals to have blood type B and
blood type AB.
FVIII differed significantly by ABO blood group.
The O group had the lowest level, 104 IU/dL (95%
CI 101–107), followed by group A with 121 IU/dL
(95% CI 116–127), group B with 134 IU/dL (95%
CI 126–142), and group AB having the highest level
of 142 IU/dL (95% CI 119–165).
In the logistic regression models (table 3), compared
with group O, only blood group AB, but not the other
blood groups, was associated with incident cognitive
impairment in an unadjusted model (OR 1.74, 95%
CI 1.12–2.72) (model 0) and the model that adjusted
for age, race, region, and sex (OR 1.82, 95% CI 1.15–
2.90) (model 1). There was no significant difference in
the association of blood group with cognitive impair-
ment by race (p interaction 5 0.17). FVIII was also
associated with incident cognitive impairment after
adjustment for age, race, region, and sex (OR 1.24,
95% CI 1.10–1.38 per 40 IU/dL higher FVIII). When
FVIII was added to the ABOmodel (model 2), the OR
for group AB was attenuated (OR 1.64, 95% CI 0.95–
2.85), and each 40 IU/dL increase in FVIII remained
associated with cognitive impairment (OR 1.23, 95%
CI 1.09–1.38). In the 1,000 bootstrapped models, add-
ing FVIII caused a mean change in the AB OR
of 20.15 (95% CI 20.56 to 0.25).
We also examined the effect of adding CVD var-
iables to the model that included FVIII. The addition
of baseline CVD and the traditional cardiovascular
risk factors hypertension, body mass index, dyslipide-
mia, diabetes, and smoking status decreased the ORs
for blood group AB to 1.42 (95% CI 0.78–2.61)
(model 3) and FVIII (per 40 IU/dL) to 1.15 (95%
CI 1.01–1.32). Current smoking (p 5 0.005), living
in the Stroke Belt (p5 0.003), diabetes (p, 0.001),
history of CVD (p5 0.02), and white race (p5 0.04)
were significantly associated with incident cognitive
impairment in this model. Diabetes and was the main
factor responsible for the change in the AB OR; how-
ever, diabetes was not significantly associated with
blood group after adjustment for age and race. To
further explore the role of diabetes as a potential
mediator in the relationship between blood group
and cognitive decline, we performed a bootstrapping
analysis, similar to that done for FVIII. Adding dia-
betes to a model adjusted for age, race, region, and sex
resulted in a nonsignificant median change in the AB
OR of 20.16 (95% CI 20.54 to 0.13).
DISCUSSION Blood type AB was associated with an
increased risk of cognitive impairment, independent
of age, race, region, and sex, with an OR of 1.82
(95% CI 1.15–2.90). FVIII was also associated with
Table 1 Distribution of CVD risk factors in cases with incident cognitive
impairment and controls
Cases with cognitive
impairment (n 5 495)
Controls
(weighted n 5 17,122) p
Sex, % 0.56
Women 59 57
Men 41 43
Race, % 0.35
Black 33 36
White 67 64
Age, y, mean (SD) 64.6 (10.2) 64.1 (8.7) 0.22
Region, % ,0.001
Stroke Belt 44 33
Buckle 22 19
Nonbelt 34 48
Hypertension, % 61 55 0.055
BMI, kg/m2, mean (SD) 30.0 (6.1) 29.2 (5.6) 0.006
Smoking, % 0.025
Current 17 12
Past 37 36
Never 45 51
Dyslipidemia, % 58 56 0.45
Diabetes, % 28 18 ,0.001
Baseline CVD, % 21 14 0.003
Abbreviations: BMI 5 body mass index; CVD 5 cardiovascular disease.
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incident cognitive impairment in this analysis, with an
OR of 1.24 (95% CI 1.10–1.38 per each 40 IU/dL
higher FVIII), and FVIII mediated approximately
20% of the association between type AB and cognitive
impairment, but this mediation was not statistically
significant. While black subjects had a higher preva-
lence of blood type AB than white subjects, there was
no significant interaction between race and blood
group or FVIII. Cardiovascular risk factors, especially
diabetes, attenuated the association of blood type with
incident cognitive impairment.
Although we are not aware of any other studies of
ABO group and cognitive impairment or dementia,
ABO influences CVD risk and many studies have
demonstrated a role for CVD risk factors in cognitive
impairment and dementia,2,5,25,26 so common etiolo-
gies for these diseases are likely. Indeed, like others4,5
we found that cases with cognitive impairment were
more likely to have many traditional CVD risk factors
present, such as diabetes and obesity. The current find-
ing of an association between blood type AB and inci-
dent cognitive impairment may represent another
connection between these diseases.
Similarly, little is currently known about the rela-
tionship between FVIII and cognitive impairment,
although it was prospectively associated with risk of vas-
cular dementia in one study of men.6 Other hemostatic
factors, including FVII, fibrinogen, D-dimer, and vWF,
are associated with dementia and cognitive impair-
ment,8 highlighting the role of coagulation in the path-
ogenesis of these disorders.
One of the main mechanisms by which ABO blood
group is thought to alter vascular risk is through its ef-
fects on vWF and FVIII.11,12 In our analyses, FVIII did
not significantly mediate the association between blood
group and incident cognitive impairment, although it
did attenuate the association and was itself associated
with cognitive impairment. This supports the hypoth-
esis that blood group affects risk of cognitive impair-
ment through alternative pathways, possibly related
to effects of the ABO glycosyltransferase. Other
known correlates of ABO that are candidate mediators
include soluble intercellular adhesion molecule-1 and
P-selectin. Levels of these molecules appear to be altered
in some types of dementia, but their role is unclear.27–29
ABO blood group also influences susceptibility to cer-
tain infectious diseases, including norovirus, cholera,
and Helicobacter pylori infection,30 through expression
of the A and B antigens on gastrointestinal epithelium.
It is possible that ABO type could alter CVD risk
through its effects on nonblood tissues.
A limitation of this study is that we were unable to
measure levels of vWF, which is also influenced by
ABO blood type. To compensate for this, we used
Table 3 Odds ratios (95% confidence intervals) for incident cognitive impairment by ABO blood group
A p B p AB p
Model 0 1.09 (0.88–1.35) 0.41 0.96 (0.71–1.30) 0.81 1.74 (1.12–2.72) 0.01
Model 1 1.15 (0.93–1.43) 0.21 1.04 (0.76–1.42) 0.80 1.82 (1.15–2.90) 0.01
Model 2 1.03 (0.80–1.31) 0.85 0.88 (0.62–1.27) 0.50 1.64 (0.95–2.85) 0.08
Model 3 0.98 (0.75–1.28) 0.86 0.97 (0.66–1.42) 0.86 1.42 (0.78–2.61) 0.25
All models use blood group O as the reference group. Model 0: unadjusted; model 1: adjusted for age, race, region, and sex;
model 2: adjusted for all previous variables and factor VIII; model 3: adjusted for all previous variables and baseline
cardiovascular disease, hypertension, body mass index, dyslipidemia, diabetes, and smoking status.
Table 2 Prevalence of blood types by race and incident cognitive impairment status in the REGARDS cohort
Blood type
A B AB O
n (na) % n (na) % n (na) % n (na) %
Cases 205 41 62 13 30 6 198 40
Black 55 34 28 17 18 11 62 38
White 150 45 34 10 12 4 136 41
Controls 233 (6,870) 40 82 (2,377) 14 24 (628) 4 248 (7,247) 42
Black 101 (2,431) 39 46 (1,000) 16 14 (364) 6 95 (2,355) 38
White 132 (4,439) 41 36 (1,377) 13 10 (264) 2 153 (4,892) 45
Abbreviation: REGARDS 5 Reasons for Geographic and Racial Differences in Stroke.
aWeighted.
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measurements of FVIII, which circulates bound to
vWF and is highly correlated with vWF.31 However,
we may have underestimated the effect of coagulation
factors in the association between ABO type and inci-
dent cognitive impairment by using only FVIII. We
were also unable to measure intercellular adhesion
molecule-1 or P-selectin, so cannot assess their potential
contribution. Another limitation was the use of inferred
ABO group based on ABO genotype information and
not clinical antigen testing, a limitation shared by most
epidemiologic studies of ABO. Because blood type O
results from a nonfunctionalABO product, it is possible
that rare variants with this phenotype were misclassi-
fied. However, this would be expected to bias our re-
sults toward the null hypothesis. Our study relied on
test-based determination of cognitive impairment, and
we lack the information that a clinical evaluation would
provide to detect dementia. Finally, because the defini-
tion of incident cognitive impairment was based on
age-, race-, sex-, and education-adjusted mean scores
on cognitive tests (a strength of our design), we could
not examine potential mediation of racial disparities in
incident cognitive impairment by ABO status.
The strengths of this study include the use of data
from a large, prospective cohort study designed to
investigate cardiovascular risk factors and outcomes,
which provided a large number of 495 cases with inci-
dent cognitive impairment over a short follow-up. This
study design allowed longitudinal assessment of cogni-
tive impairment in relation to baseline risk factors. The
REGARDS cohort is also geographically diverse within
the United States, and includes a large proportion of
black subjects. Our definition of incident cognitive
impairment considered the effects of age, race, sex,
and education, utilized testing in multiple cognitive
domains, and used a cutpoint to define impairment
that has clinical relevance, strengthening our ability
to identify those with significant impairment.
The results of our study support the hypothesis that
ABO blood group represents a link between cardiovas-
cular risk and cognitive function. Blood group AB and
higher FVIII were associated with cognitive decline in a
large cohort of both black and white Americans, and
while higher FVIII levels were seen in those with type
AB, mediation of the group AB–cognitive decline asso-
ciation by FVIII was nonsignificant. This indicates that
the effect may be the result of other pathways influ-
enced by the ABO glycosyltransferase. Further work is
needed to confirm these results and to determine the
underlying mechanisms responsible.
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Save These Dates for AAN CME Opportunities!
Mark these dates on your calendar for exciting continuing education conferences by the American
Academy of Neurology. Learn more at AAN.com/conferences.
AAN Fall Conference
• October 31-November 2, 2014, Las Vegas, NV, The Cosmopolitan of Las Vegas
AAN Annual Meeting
• April 18-25, 2015, Washington, DC, Walter E. Washington Convention Center
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